Company Summary - Phytopharm PLC (LSE:PYM)
10.75p
0.25p
(-2.33%)
FTSE Fledgling Pharmaceuticals & BiotechnologyMarket cap: £37.268m
Review a company's summary page in more detail and see the key fundamentals at a glance. Sign-up to Premium now to make your investment decisions.
Sign-up to Premium's Free 7 Day trial See an improved company summary
Summary
Pharmaceutical development and functional food company
| Financials - Annual Report (30/09/2009) | ||
|---|---|---|
| Turnover | £m | 0.87 |
| Pre-tax Profit | £m | -4.2 |
| EPS | p | -3.42 |
| DPS | p | - |
| Dividend Yield | % | |
| Director | Board Role |
|---|---|
| Alistair Taylor | Chairman |
| Sandy Morrison | Chief Executive |
Products Brands & Subsidiaries
Products & Brands
Cogane; Hoodia extract; Myogane; P1; P54; P54v; P55; P57; P58; P59; P61; P63; P64; P7v; PYM60001 series; PYM60004 series; PYM60086...
Subsidiaries
Phytotech Ltd
Broker Sentiment (1 brokers)
Strong SellStrong Buy
| Heading | Date |
|---|---|
| Notice of AGM | 02/03/2010 |
| Interim Management Statement | 11/02/2010 |
| Directorate Change | 15/01/2010 |
For more information
and investor relations, visit the
Phytopharm PLC company website: